-
公开(公告)号：CA2344262A1
公开(公告)日：2000-03-30
申请号：CA2344262
申请日：1999-09-17
Applicant: BASF AG
Inventor： CALDERWOOD DAVID , ARNOLD LEE D , DENG BOJUAN B , MAZDIYASNI HORMOZ , HIRST GAVIN , RAFFERTY PAUL , JOHNSTON DAVID N , TOMETZKI GERALD B , MUNSCHAUER RAINER , TWIGGER HELEN L
IPC: A61K31/519 , A61P1/04 , A61P3/10 , A61P9/00 , A61P11/00 , A61P15/00 , A61P17/02 , A61P19/02 , A61P27/00 , A61P29/00 , A61P35/00 , A61P37/02 , A61P43/00 , C07D487/04 , A61K31/505
Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferative is a factor. These compounds can be used to treat cancer, hyperproliferation disorders, rheumatoid arthritis, disorders of the immune system, transplant rejection, and inflammatory disorders.
-
公开(公告)号：AT247657T
公开(公告)日：2003-09-15
申请号：AT00963554
申请日：2000-09-15
Applicant: BASF AG
Inventor： HIRST GAVIN C , CALDERWOOD DAVID , WISHART NEIL , RAFFERTY PAUL , RITTER KURT , ARNOLD LEE D , FRIEDMAN MICHAEL M
IPC: A61K31/519 , A61K31/5377 , A61K38/22 , A61P1/04 , A61P1/16 , A61P3/10 , A61P5/14 , A61P7/06 , A61P9/00 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/00 , A61P13/12 , A61P15/16 , A61P17/02 , A61P17/06 , A61P19/02 , A61P25/00 , A61P27/02 , A61P29/00 , A61P31/04 , A61P31/22 , A61P33/02 , A61P35/00 , A61P35/02 , A61P37/06 , A61P43/00 , C07D487/04 , C07F9/6561 , C07D239/00 , C07D231/00
Abstract: The present invention is directed to pyrazolopyrimidine derivatives which are useful as kinase inhibitors and as such are useful for affecting angiogenesis and diseases and conditions associated with angiogenesis.
-
公开(公告)号：AU753555C
公开(公告)日：2003-07-03
申请号：AU6048499
申请日：1999-09-17
Applicant: BASF AG
Inventor： HIRST GAVIN C , CALDERWOOD DAVID , MUNSCHAUER RAINER , RAFFERTY PAUL , ARNOLD LEE D , JOHNSTON DAVID N
IPC: A61K31/519 , A61P1/04 , A61P3/10 , A61P5/14 , A61P9/00 , A61P11/00 , A61P11/06 , A61P13/12 , A61P15/00 , A61P17/06 , A61P19/02 , A61P21/00 , A61P25/00 , A61P27/02 , A61P29/00 , A61P31/04 , A61P31/12 , A61P31/18 , A61P35/00 , A61P37/00 , A61P43/00 , C07D487/04 , C07F9/6561 , C07F9/6584 , A61K31/505
Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts and metabolites thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases, whose activity is inhibited by these chemical compounds, are involved in immunologic, hyperproliferative, or angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyper proliferative disorders, rheumatoid arthritis, disorders of the immune system, transplant rejections and imflammatory disorders.
-
34.发明专利
公开(公告)号：HU0200310A2
公开(公告)日：2002-11-28
申请号：HU0200310
申请日：1999-11-04
Applicant: BASF AG
Inventor： ARNOLD LEE D , DOYLE KEVIN J , ERICSSON ANNA M , HOCKLEY MICHAEL , RAFFERTY PAUL , STEELE ROBERT W , WILKINS DAVID J
IPC: A61K31/416 , A61K31/4162 , A61K31/4427 , A61K31/4433 , A61K31/4439 , A61P1/04 , A61P1/16 , A61P5/14 , A61P7/10 , A61P9/00 , A61P9/10 , A61P11/00 , A61P15/08 , A61P17/02 , A61P17/06 , A61P19/02 , A61P19/08 , A61P27/00 , A61P27/06 , A61P35/00 , A61P37/00 , A61P43/00 , C07D231/54 , C07D401/04 , C07D401/12 , C07D403/12 , C07D409/04 , C07D413/04 , C07D417/12 , C07D491/04 , C07D491/048 , C07D495/04
Abstract: This invention relates to certain 3-aryl or 3-heteroaryl pyrazoles with 4,5(3,4)-bicyclic ring fusion which are inhibitors of protein kinase activity, of which some are novel compounds, to pharmaceutical compositions containing these pyrazoles and to processes for preparing these pyrazoles.
-
公开(公告)号：AU752474B2
公开(公告)日：2002-09-19
申请号：AU6047599
申请日：1999-09-17
Applicant: BASF AG
Inventor： CALDERWOOD DAVID , ARNOLD LEE D , MAZDIYASNI HORMOZ , HIRST GAVIN , DENG BOJUAN B , RAFFERTY PAUL , TOMETZKI GERALD B , JOHNSTON DAVID N , TWIGGER HELEN L , MUNSCHAUER RAINER
IPC: A61K31/519 , A61P1/04 , A61P3/10 , A61P9/00 , A61P11/00 , A61P15/00 , A61P17/02 , A61P19/02 , A61P27/00 , A61P29/00 , A61P35/00 , A61P37/02 , A61P43/00 , C07D487/04 , A61K31/505
Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferative is a factor. These compounds can be used to treat cancer, hyperproliferation disorders, rheumatoid arthritis, disorders of the immune system, transplant rejection, and inflammatory disorders.
-
Patent Agency Ranking
公开(公告)号：ZA200102201B
公开(公告)日：2002-03-15
申请号：ZA200102201
申请日：2001-03-16
Applicant: BASF AG
Inventor： CALDERWOOD DAVID , ARNOLD LEE , GAVIN MAZDIYASNI HORMOZ HIRST , DENG BOJUAN , JOHNSTON DAVID N , RAFFERTY PAUL , TOMETZKI GERALD B , TWIGGER HELEN L , MUNSCHAUER RAINER
IPC: A61K31/519 , A61P1/04 , A61P3/10 , A61P9/00 , A61P11/00 , A61P15/00 , A61P17/02 , A61P19/02 , A61P27/00 , A61P29/00 , A61P35/00 , A61P37/02 , A61P43/00 , C07D487/04 , C07D , A61K
Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferative is a factor. These compounds can be used to treat cancer, hyperproliferation disorders, rheumatoid arthritis, disorders of the immune system, transplant rejection, and inflammatory disorders.
-
公开(公告)号：PL346700A1
公开(公告)日：2002-02-25
申请号：PL34670099
申请日：1999-09-17
Applicant: BASF AG
Inventor： HIRST GAVIN C , CALDERWOOD DAVID , MUNSCHAUER RAINER , RAFFERTY PAUL , ARNOLD LEE D , JOHNSTON DAVID N
IPC: A61K31/519 , A61P1/04 , A61P3/10 , A61P5/14 , A61P9/00 , A61P11/00 , A61P11/06 , A61P13/12 , A61P15/00 , A61P17/06 , A61P19/02 , A61P21/00 , A61P25/00 , A61P27/02 , A61P29/00 , A61P31/04 , A61P31/12 , A61P31/18 , A61P35/00 , A61P37/00 , A61P43/00 , C07D487/04 , C07F9/6561 , C07F9/6584 , A61K31/505
Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts and metabolites thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases, whose activity is inhibited by these chemical compounds, are involved in immunologic, hyperproliferative, or angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyper proliferative disorders, rheumatoid arthritis, disorders of the immune system, transplant rejections and imflammatory disorders.
-
公开(公告)号：BG105481A
公开(公告)日：2001-12-31
申请号：BG10548101
申请日：2001-04-27
Applicant: BASF AG
Inventor： DOYLE KEVIN J , RAFFERTY PAUL , STEELE ROBERT W , WILKINS DAVID J , HOCKLEY MICHAEL , ARNOLD LEE D , ERICSSON ANNA M
IPC: A61K31/416 , A61K31/4162 , A61K31/4427 , A61K31/4433 , A61K31/4439 , A61P1/04 , A61P1/16 , A61P5/14 , A61P7/10 , A61P9/00 , A61P9/10 , A61P11/00 , A61P15/08 , A61P17/02 , A61P17/06 , A61P19/02 , A61P19/08 , A61P27/00 , A61P27/06 , A61P35/00 , A61P37/00 , A61P43/00 , C07D231/54 , C07D401/04 , C07D401/12 , C07D403/12 , C07D409/04 , C07D413/04 , C07D417/12 , C07D491/04 , C07D491/048 , C07D495/04 , A61K31/415 , A61K31/425 , A61K31/44 , A61K31/445 , A61K31/505 , A61K31/53 , A61P29/00
Abstract: The invention relates to certain 3-aryl or 3-heteroaryl pyrazoles with 4,5(3,4)-bicyclic ring fusion of formula which are inhibitors of protein kinase activity, of which some are novel compounds, to pharmaceutical compositions containing these pyrazoles and to processes for preparing these pyrazoles. 77 claims
-
公开(公告)号：BR9915132A
公开(公告)日：2001-08-07
申请号：BR9915132
申请日：1999-11-04
Applicant: BASF AG
Inventor： DOYLE KEVIN J , RAFFERTY PAUL , STEELE ROBERT W , WILKINS DAVID J , HOCKLEY MICHAEL , ARNOLD LEE D , ERICSSON ANNA M
IPC: A61K31/416 , A61K31/4162 , A61K31/4427 , A61K31/4433 , A61K31/4439 , A61P1/04 , A61P1/16 , A61P5/14 , A61P7/10 , A61P9/00 , A61P9/10 , A61P11/00 , A61P15/08 , A61P17/02 , A61P17/06 , A61P19/02 , A61P19/08 , A61P27/00 , A61P27/06 , A61P35/00 , A61P37/00 , A61P43/00 , C07D231/54 , C07D401/04 , C07D401/12 , C07D403/12 , C07D409/04 , C07D413/04 , C07D417/12 , C07D491/04 , C07D491/048 , C07D495/04 , A61K31/415 , A61K31/425 , A61K31/44 , A61K31/445 , A61K31/505 , A61K31/53 , A61P29/00
Abstract: This invention relates to certain 3-aryl or 3-heteroaryl pyrazoles with 4,5(3,4)-bicyclic ring fusion which are inhibitors of protein kinase activity, of which some are novel compounds, to pharmaceutical compositions containing these pyrazoles and to processes for preparing these pyrazoles.
-
公开(公告)号：ID29028A
公开(公告)日：2001-07-26
申请号：ID20010652
申请日：1999-09-17
Applicant: BASF AG
Inventor： HIRST GAVIN C , CALDERWOOD DAVID , MUNSCHAUER RAINER , ARNOLD LEE D , JOHNSTON DAVID N , RAFFERTY PAUL , ARNOLD LEE D
IPC: A61K31/519 , A61P1/04 , A61P3/10 , A61P5/14 , A61P9/00 , A61P11/00 , A61P11/06 , A61P13/12 , A61P15/00 , A61P17/06 , A61P19/02 , A61P21/00 , A61P25/00 , A61P27/02 , A61P29/00 , A61P31/04 , A61P31/12 , A61P31/18 , A61P35/00 , A61P37/00 , A61P43/00 , C07D487/04 , C07F9/6561 , C07F9/6584 , A61K31/505
Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts and metabolites thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases, whose activity is inhibited by these chemical compounds, are involved in immunologic, hyperproliferative, or angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyper proliferative disorders, rheumatoid arthritis, disorders of the immune system, transplant rejections and imflammatory disorders.
-
-
-
-
-
-
-
-
-
Search Results
61
records
(took 0.022 seconds)
